Kingsview Wealth Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-17,184
Closed -$2.91M – 1177
2025
Q1
$2.91M Buy
+17,184
New +$2.82M 0.05% 302
2024
Q1
– Sell
-1,661
Closed -$229K – 1022
2023
Q4
$229K Sell
1,661
-196
-11% -$25.8K 0.01% 854
2023
Q3
$226K Sell
1,857
-60
-3% -$7.99K 0.01% 843
2023
Q2
$270K Sell
1,917
-9,721
-84% -$1.34M 0.01% 777
2023
Q1
$1.65M Buy
11,638
+8,282
+247% +$1.18M 0.07% 272
2022
Q4
$525K Buy
+3,356
New +$482K 0.02% 496
2022
Q1
– Sell
-7,035
Closed -$1.22M – 895
2021
Q4
$1.22M Sell
7,035
-6,284
-47% -$956K 0.05% 338
2021
Q3
$1.94M Buy
13,319
+1,769
+15% +$259K 0.09% 228
2021
Q2
$1.54M Buy
11,550
+2,154
+23% +$282K 0.08% 276
2021
Q1
$1.22M Buy
9,396
+340
+4% +$41.9K 0.07% 291
2020
Q4
$1.08M Buy
9,056
+1,088
+14% +$133K 0.08% 256
2020
Q3
$912K Buy
7,968
+1,797
+29% +$212K 0.08% 242
2020
Q2
$703K Buy
6,171
+816
+15% +$86.5K 0.07% 265
2020
Q1
$430K Buy
5,355
+1,623
+43% +$168K 0.06% 290
2019
Q4
$399K Buy
3,732
+1,540
+70% +$161K 0.05% 321
2019
Q3
$235K Buy
+2,192
New +$225K 0.04% 382

Other funds holding DGX

Kingsview Wealth Management's DGX Position: Q2 2025 in Review

Kingsview Wealth Management sold out of Quest Diagnostics (DGX) in Q2 2025, closing a stake of 17,184 shares — an estimated $2.91M sold.

Kingsview Wealth Management first reported a position in DGX in Q3 2019 and held it in 16 quarters. The position peaked at $2.91M in Q1 2025. 991 funds tracked by Wall St. Rank hold DGX as of Q2 2025.

  • Kingsview Wealth Management reported no remaining Quest Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Kingsview Wealth Management sold 17,184 Quest Diagnostics shares in Q2 2025, an estimated $2.91M.
  • Kingsview Wealth Management first reported a position in Quest Diagnostics in Q3 2019 and held it in 16 quarters.
  • Kingsview Wealth Management's Quest Diagnostics position peaked at $2.91M in Q1 2025.
  • 991 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2025.

Based on Kingsview Wealth Management's 13F filing for Q2 2025, filed 8 Aug 2025.